Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 16/20 | 0.60 |
| ▸ | NPC1 | O15118 | 15/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.60 |
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366577 | 0.79 | BRAF (0.60) | RAB9ANPC1BRAFSMN1; SMN2MEN1 | |
| SCHEMBL1367764 | 0.79 | BRAF (0.58) | RAB9ANPC1BRAFROCK1PIK3CA | |
| SCHEMBL1367758 | 0.79 | BRAF (0.58) | RAB9ANPC1BRAFROCK1PIK3CA | |
| SCHEMBL1367761 | 0.79 | BRAF (0.58) | RAB9ANPC1BRAFROCK1PIK3CA | |
| SCHEMBL1365186 | 0.79 | BRAF (0.59) | RAB9ANPC1BRAFSMN1; SMN2MEN1 | |
| SCHEMBL1366062 | 0.75 | BRAF (0.62) | BRAFPIK3CAMTOR | |
| SCHEMBL1366429 | 0.75 | PIK3CA (0.48) | RAB9ANPC1PKMBRAFSMN1; SMN2 | |
| SCHEMBL17420246 | 0.75 | NPC1 (0.55) | RAB9ANPC1BRAFKMT2APIK3CA | |
| SCHEMBL1369483 | 0.74 | BRAF (0.63) | RAB9ANPC1BRAFPIK3CAMTOR | |
| SCHEMBL1368109 | 0.74 | BRAF (0.52) | RAB9ANPC1BRAFHPGDNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | claimed |
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K5, MAP3K1, PRKACA | RAB9A 991/4885NPC1 1424/4885PKM 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.